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Abstract 
 
Atherogenesis is the pathogenetic process leading to formation of the atheroma lesion. It is 
associated to a chronic inflammatory state initially stimulated by an aberrant accumulation of lipid 
molecules beyond the endothelial barrier. This event triggers a cascade of deleterious events 
mainly through immune cells stimulation with the consequent liberation of potent pro-inflammatory 
and tissue damaging mediators. The atherogenetic process implies marked modifications of 
endothelial cell functions and a radical change in the endothelial-leukocyte interaction pattern. 
Moreover, accumulating evidence shows an important link between microvascular and 
inflammatory responses and major cardiovascular risk factors. This review illustrates the current 
knowledge on the effects of obesity, hypercholesterolemia and diabetes on microcirculation; their 
pathophysiological implications will be discussed. 
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Anatomy of microcirculation 
In most organs, microcirculation is composed of three anatomically and functionally distinct 
segments: arterioles, capillaries and venules. Arterioles are well innervated and anatomically 
characterized by endothelium surrounded by a smooth muscle cell containing wall and a diameter 
ranging from 10 to 100 m. Typically, arterioles display a divergent branching pattern so that blood 
flows from one arteriole into two branches at each bifurcation. Arterioles are highly responsive to 
sympathetic vasoconstriction and represent a major player in the regulation of systemic vascular 
resistance. Because of these characteristics, the regulation of blood flow and ultimately oxygen 
delivery represent the primary function of arterioles. In addition arterioles, by participating to the 
regulation of capillary hydrostatic pressure, influence capillary fluid exchange [1, 2].  
Blood flows from arterioles into capillaries, 5-10 M calibre single endothelial cell layer vessels 
surrounded by basement membrane and devoid of smooth muscle cell wall and innervation. In 
some organs, however, a circular band of smooth muscle at the entrance of the capillary 
(precapillary sphincter) can regulate the number of perfused capillaries [1, 2].  
Capillaries ensure large surface area and relatively high permeability to favour the exchange of 
fluids, gases, electrolytes and macromolecules. In different organs, the endothelial wall differs for 
its structural organization and permeability. In the liver, spleen and bone marrow gaps in both the 
endothelial layers and the basement membrane result in very high permeability of capillaries. 
Fenestrated capillaries are present in the intestinal mucosa, renal glomeruli and exocrine glands 
where endothelial cells display wide intercellular clefts surrounded by a continuous basement 
membrane. Continuous capillaries are found in the central nervous system, skin, muscle and the 
lung where intercellular gaps are tight and basement membrane is continuous. These capillaries 
display the lowest permeability [1-3]. 
Venules are small exchange vessels but with a larger caliber than the corresponding arterioles (10-
50 M caliber), resulting in a lower flow velocity and wall shear stress that promote leukocyte 
margination and facilitate adhesion to the vessel wall. Venules are composed of an endothelial 
cells layer surrounded by a basement membrane. Smooth muscle cells are present in larger 
venules but not in small postcapillary venules. The presence of smooth muscle and symphatetic 
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innervation in larger venules allows the regulation of venules tone and therefore capillary 
hydrostatic pressure [2, 3]. Due to their anatomical architecture resulting in relatively low 
permeability, fluid and macromolecules exchange occurs predominantly at venular junctions. 
Leukocyte margination is favoured in venules because of erythrocytes tendency to aggregate at 
low shear stress forces occurring in the central portion of venules. Erythrocyte aggregation in turn 
pushes leukocytes toward the vessel wall. In addition, the flow discharged by a capillary into a 
venule at site of confluent junctions is located to a region close to the venule wall thus promoting 
leukocytes to take contact with the endothelium. Finally, the most important factor determining the 
prevalence of leukocyte adhesion to venule walls during inflammation is the selective expression of 
adhesion molecules by venule but not arteriole or capillary endothelial cells [1, 2, 4]. 
 
 
Inflammatory state of microcirculation associated to atherogenesis. 
Under normal conditions, vascular endothelial cells subserve several tasks that constitute the 
“endothelial function” including the regulation of blood flow, blood fluidity, vessel wall permeability 
and interactions with circulating leukocytes. 
Blood flow fluidity is modulated through the regulation of the tone of surrounding vascular smooth 
muscle cells, that in turn, depends on the balance between vasoconstriction and vasorelaxant 
signals. Endothelial cells-dependent vasorelaxation of SMC is achieved through the production of 
nitric oxide. Nitric oxide is highly reactive (having a lifetime of a few seconds), yet diffuses freely 
across membranes. NO acts through the stimulation of the heterodimeric enzyme soluble 
guanylate cyclase, with subsequent formation of cyclic GMP. Cyclic GMP activates protein kinase 
G, which causes phosphorylation of myosin light chain phosphatase, and therefore inactivation of 
myosin light-chain kinase, causing smooth muscle relaxation through the dephosphorylation of the 
myosin light chain [5]. 
Endothelial cells actively inhibit blood coagulation ensuring blood fluidity through several 
mechanisms such as the expression of coagulation cascade inhibitors including heparane sulphate 
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proteoglycans, inhibitors of tissue factor pathways, and thrombomodulin. In addition ECs inhibit 
platelet activation by releasing NO and prostacyclin [6, 7]. 
In physiological conditions, plasmatic proteins are contained inside vascular lumen of continuous 
capillaries, the structure of junctions between adjacent ECs that include tight and adherens 
junctions. The permeability properties of capillaries depend on the structural organization and the 
presence of intercellular junction structures that varies considerably in different anatomical 
locations. Junctional structures are tighter in the capillaries of the central nervous system, in the 
liver and spleen sinusoidal capillaries and are characterized by discontinuous intercellular junctions 
that enable blood contact with underlying tissue. However, in most tissues, capillary ECs normally 
block extravasation of plasmatic proteins as small as albumin. On the other hand, they operate 
active transport of proteins from capillary lumen to tissue via vesicular transport [8]. 
In normal conditions, endothelial cells have rare interactions with circulating leukocytes, thus 
representing a barrier between tissues and inflammatory cells. In non-inflamed vasculature 
leukocyte-ECs, interaction is limited because of the very low constitutive expression of surface 
adhesion molecules such as, ICAM-1, VCAM-1 and E-selectin as well as the compartimentalization 
of P-selectin and chemokines into endothelial intracellular vescicles named Weibel-Palade bodies 
[2, 9]. In addition, resting ECs stimulated by shear stress express NO that inhibits proinflammatory 
genes transcription, release of Wiebel Palade bodies content and leukocyte activation (discussed 
below). 
Atherosclerosis involves the formation of lesions in the arteries characterized by lipid accumulation, 
inflammation, cell death and fibrosis. These lesions known as atherosclerotic plaques grow and 
evolve over time with the consequent decrease of the vasal section. A limited and often insufficient 
blood flow accompanied by stenosis due to modification of blood vessel plasticity, leads to clinical 
complications. However, the most serious complications arise from lesions rupture and sudden 
exposure of thrombotic substances to circulating blood leading to abrupt formation of blood clots 
and occlusion. The atherogenic process involves three major steps: an early and persisting 
inflammatory component, a proliferative response and, ultimately, a mural thrombosis that is 
potentially responsible for vascular occlusion. 
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Although atherosclerotic lesions occur in large arteries, the upregulated expression of adhesion 
molecules characteristic of EC activation, the reduced endothelium-dependent vasodilatation as 
well as oxidative stress are not confined to lesion-prone arteries where factors other than EC 
activation (e.g. elevated shear stress) might act to determine atheroma formation. Atherosclerosis 
is associated with a systemic inflammatory state characterized by endothelial and blood cells 
activation as well as increased plasmatic concentration of inflammatory factors and endothelial 
dysfunction consisting in reduced endothelium-dependent vasodilation [10]. Parameters such as 
the circulating concentrations of proinflammatory factors or soluble isoforms of adhesion molecules 
have been proposed as biomarkers for the assessment of cardiovascular risk. Enhanced 
production of inflammatory mediators such as cytokines, chemokines and reactive oxygen species 
occur in the atherosclerotic lesions determining and sustaining local intramural inflammation. 
However, inflammatory mediators can also be released in the circulation determining systemic 
inflammation with the involvement of the microcirculation. Alternatively, cardiovascular risk factors 
as for example elevated blood cholesterol levels, hypertension, diabetes, obesity and cigarette 
smoke might directly stimulate microvascular endothelial cells activation with consequent release 
of inflammatory mediators and soluble isoforms of adhesion molecules, thus determining 
microvascular dysfunction and the atherosclerosis-associated systemic inflammatory state [11]. In 
support of this hypothesis, many observations have indicated that the presence of cardiovascular 
risk factors such as hypercholesterolemia, obesity, hypertension and diabetes induce 
microvascular responses consistent with the induction of an inflammatory phenotype [12]. In both 
scenarios, due to its preponderant surface area, microcirculation would quantitatively represent the 
major source of circulating inflammatory mediators. 
Accumulating evidence suggests that oxidative stress represents a main pathogenic mechanism 
underlying the development and the progression of atherosclerosis. Oxidative stress is defined as 
an imbalance between oxidants and antioxidants in favour of the former. Reactive oxygen species 
(ROS), including superoxide anions (O2
-), hydrogen peroxide, and hydroxyl radicals are produced 
by a variety of cell types including endothelial cells, phagocytes and smooth muscle cells. Free 
radicals such as O2
- and hydroxyl radicals are highly reactive and hold exalted oxidizing activity. 
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The activity of enzymes such as nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
and xanthine oxidase, as well as the mitochondrial redox cycle can generate ROS. 
Endothelial cells, vascular smooth muscle cells, and monocytes/macrophages cells contain potent 
defence systems against ROS, including the enzymes superoxide dismutase, catalase, and 
glutathione peroxidase, and non-enzymatic antioxidants. Nonetheless, excessive ROS production 
may occur and cause endothelial dysfunction, inflammation of the arterial wall, and atherosclerosis. 
Endothelial dysfunction is a very early marker of endothelial suffering. Being located between the 
blood and the vessel wall, the vascular endothelium has a strategic position in the cardiovascular 
system. NO produced by the endothelium has potent vasorelaxant activity, but it is also highly 
reactive with O2. NO oxidation generates peroxynitrite, which is devoid of vasodilatory properties. 
Reduced NO bioavailability is therefore associated with impaired response to all vasodilators that 
act primarily by stimulating the endothelial release of NO. Notably, increased oxidative stress and 
endothelial dysfunction have been demonstrated in subjects with cardiovascular risk factors such 
as diabetes, hypercholesterolemia, hypertension, and in cigarette smokers. NO also influences 
other functions of the vascular endothelium as for example the regulation of blood coagulation and 
the recruitment of circulating leukocytes. By downregulating the surface expression of adhesion 
molecules, NO contributes to limit endothelial cell-leukocyte interaction thus dampening 
inflammation. In addition, NO exerts antithrombogenic and antiproliferative effects [13]. Reduced 
NO levels would therefore negatively impact vascular physiology. In addition, increased ROS 
concentrations translates into augmented oxidation of low-density lipoproteins, which are taken up 
by macrophages, cause foam cell formation and induce vascular inflammation [14-16]. A relevant 
quota of superoxide comes from the transfer of electrons from NADPH to oxygen catalyzed by 
membrane-bound NADPH oxidases expressed by endothelial cells, vascular smooth muscle cells, 
fibroblasts, and phagocytes. Atherosclerosis is associated with increased expression of NADPH 
oxidases. Thus, it is not surprising that the activity of such enzymes represents a major target of 
pharmacological treatment aimed at reducing atherosclerosis progression. In this context, it is 
worthy to point out that the NADPH-oxidase–mediated O2- production is upregulated by 
angiotensin II (Ang II), therefore Ang II type 1 (AT1)-receptor blockade can effectively reduce 
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oxidative stress and inflammation in patients with hypertension, established coronary heart 
disease, or metabolic syndrome [17]. Moreover, hydroxymethylglutarylcoenzyme A reductase 
inhibitors (statins) inhibit cholesterol synthesis, as well as the formation of the of NADPH oxidases, 
thereby attenuating oxidative stress. As a result, statins and renin-angiotensin system blockers 
improve endothelium-dependent vasodilation and reduce circulating inflammatory molecules [18]. 
 
 
Oxidative stress and hypercholesterolemia 
Microvascular inflammatory and thrombogenic response has been observed in several studies 
involving animal models of diet-induced hypercholesterolemia. This microvascular endothelial 
dysfunction is characterized by oxidative stress [19-21]. The resulting increased ROS generation 
and reduced NO bioavailability translate into impaired endothelium-dependent arteriolar 
vasodilation [22] and increased expression of adhesion molecules in the post capillary venules 
endothelium [23], the latter causing increased leukocyte and platelets recruitment. In turn, the 
increased interaction between EC and leukocytes sustains oxidative stress [19, 24]. 
Oxidative stress in post-capillary venules has been shown to occur early upon the onset of 
hypercholesterolemia [25, 26]. Increased ROS production also contributes to the generation of 
oxidized low-density lipoproteins that, in turn, are known mediators of inflammation and vascular 
dysfunction in atherosclerosis [27, 28]. 
Among ROS species, whose generation is elicited by hypercholesterolemia, superoxide is the best 
characterized and its metabolism can be taken as paradigmatic of other ROS species.  
Superoxide formation can arise by reactions catalyzed by different enzymes including xanthine 
oxidase, lipoxygenase and NADPH oxidase. The latter is expressed by multiple cell types such as 
endothelial cells, smooth muscle cells, monocytes, T lymphocytes and platelets [29-31].  
Because of its intrinsic toxicity, superoxide levels are controlled by a tight balance between 
production and degradation, the latter occurring primarily by the endogenous scavenger enzyme 
superoxide dismutase (SOD). Although SOD competes with NO for superoxide, superoxide-NO 
interaction is favoured and generates the toxic product peroxynitrite yet depleting NO. 
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Increased ROS production might lead to reduced NO bioavailability by an indirect mechanism also. 
For example, the activity of NO synthase (NOS) isoform expressed by ECs (eNOS) is pivotal for 
normal regulation of vascular tone and the maintenance of antithrombocgenic and anti-
inflammatory endothelial cell phenotype. However, it requires sufficient levels of the cofactors such 
as tetrahydrobiopterin, that are impaired in the presence of elevated ROS production. Notably, in 
absence of adequate tetrahydrobiopterin concentration, eNOS turns to generate superoxide 
instead of NO, thus further contributing to the NO/ROS imbalance [32]. In addition, NOS activity 
can also be reduced as a result of the increased levels of asymmetric dimethylarginine (ADMA) 
occurring during hypercholesterolemia [33]. Interestingly, in hypercholesterolemic patients with 
impairment of the endothelium-dependent dilation of the epicardial coronary arteries, vascular 
function can be restored reducing serum cholesterol [34]. The mechanism underlying this 
dysfunction involves the reduced ability of substances such as acetylcholine or bradykinin that 
stimulate EC to release NO that, in turn, acts on VSMC. Stimulation with a NO donor, restores 
normal vasodilation thus indicating that VSMC responsiveness to NO is preserved [22, 23]. Two 
additional observations further support the hypothesis that the hypercholesterolemia-induced 
vascular dysfunction is, at least in part, mediated by ROS/NO imbalance: administration of L-
arginine, substrate of NO synthase, or of superoxide dismutase reversed vascular function 
impairment in hypercholesterolemic animals [22, 35]. 
Oxidative stress to which microvascular endothelium is exposed is significantly sustained by EC 
interaction with inflammatory cells. Such interaction occurs primarily in post capillary venules but 
can affect the function of other microvascular segments. For example it has been shown that 
neutrophils adhesion to venular endothelium contributes to arteriolar dysfunction [22]. 
 
Leukocyte-endothelial cell interaction 
Inflammatory state, as well as hypercholesterolemia, induces upregulated expression of adhesion 
molecules by EC and circulating leukocytes thus favouring blood cell recruitment. 
Adhesion molecules, with some exception, belong to one of three major families: selectins, 
integrins and immunoglobulins. Selectins bind to sialyl-Lewis X-like carbohydrate ligands 
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presented by sialomucin-like surface moleculses including P-selectin glycoprotein ligand 1 (PSGL-
1) [36]. 
P and E-selectin expressions are generally upregulated on endothelium in most inflammatory 
processes and represent important determinants for leukocyte recruitment. L-selectin on leukocyte 
membrane can also bind PSGL-1 expressed on other leukocyte thus enabling leukocyte capture by 
intravascular adherent leukocytes. In the context of inflammation, P selectin plays a pivotal role 
among molecules expressed by endothelial cells. P selectin can be rapidly translocated to the 
plasmatic membrane of endothelial cells from the Weibel-Palade bodies upon exposure to 
inflammatory stimuli. Once on the surface, P selectin supports both leukocyte-EC and platelets-EC 
interaction. P selectin deficiency partially protects from atherosclerosis and neointima formation 
after vascular injury [37, 38]. 
The adhesion properties of selectins and their ligands are regulated by post-translational 
modifications, topographical distribution and shedding, all of which are influenced by inflammation. 
Integrins are transmembrane  heterodimers that bind many extracellular matrix proteins and 
certain immunoglobulin-like adhesion molecules on other cells [39, 40]. The most relevant integrins 
for leukocyte recruitment are the heterodimer  lymphocyte function-associated antigen 1 
(LFA-1),  very late antigen 4 (VLA-4) and  Integrins bind a variety of surface molecules 
of the immunoglobulin superfamily including intercellular adhesion molecule 1 (ICAM-1), vascular 
cell adhesion molecule 1 (VCAM-1), both important ligands for VLA-4 and mucosal addressin cell 
adhesion molecule 1 (MAdCAM-1) representing the main ligand for . Other relevant members 
of the immunoglobulin-like adhesion molecules group include and PECAM-1 (CD31) [41], junction 
adhesion molecule (JAM)-A, JAM-B and JAM-C [11, 42] and endothelial cell-selective adhesion 
molecule (ESAM) [43]. 
The current paradigm of the leukocyte recruitment describes a multi-step process named leukocyte 
adhesion cascade. The number of molecules implicated in each step and the multiplicity of the 
regulatory mechanisms involved afford high degree of specificity and a wide variety of potential 
therapeutic targets. The leukocyte adhesion cascade begins with first contact between leukocyte 
and endothelium in the “tethering” step. During the second step named “rolling” cell activation 
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occurs through the action of chemokines and chemokine-independent mechanisms. During the 
rolling step, L-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) on the leukocyte, interact with 
sugars and P-selectin, respectively, on the endothelial cells. Ligation of immunoglobulins, such as 
intercellular adhesion molecule-1 (ICAM-1), on the endothelium by integrins CD11b/CD18 on the 
leukocyte participates to strengthen cell-cell interaction and turns some of the rolling leukocytes 
into firmly adherent cells [44, 45]. In the final stage, migration into tissue occurs in the presence of 
appropriate stimuli for both EC and leukocytes. 
Increased leukocyte adhesion is widely diffused in the venular segments of microcirculation in 
prolonged hypercholesterolemic conditions, while the large vessels display distinct foci where 
leukocyte recruitment occurs [19-21, 23]. Microcirculation response to atherosclerosis-fostering 
conditions, such as hypercholesterolemia, includes upregulation of P-selectin and ICAM-1 in 
postcapillary venules. Leukocyte recruitment in the post-capillary venules has been found to be 
markedly reduced by P-selectin neutralization [20]. Enhanced leukocyte adherence to the 
endothelium of post capillary venules has been shown in animal models of diet-induced 
hypercholesterolemia. 
Animal studies have shown that early upon the establishment of hypercholesterolemia, the 
predominant leukocyte subset to be recruited in post-capillary venules is represented by 
neutrophils [46]. A key role for oxidative stress has been demonstrated in the recruitment of 
neutrophils induced by elevated cholesterol levels. Mice overexpressing superoxide scavenger 
SOD did not display increased leukocyte adhesion in the post-capillary venules. In keeping, mice 
deficient for the p47phox component of the NADPH oxidase did not display cholesterol induced 
neutrophil recruitment. 
 
Role of recruited leukocyte in microvascular inflammation 
Bone marrow chimera experiments have shown that NADPH oxidase expressed by both 
endothelial cells and by leukocytes are important for determining the inflammatory phenotype 
associated of post-capillary venules [19]. This finding suggests that leukocyte recruitment 
reinforces inflammatory stimulation by locally increasing superoxide production. The enhanced 
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expression of superoxide due to leukocyte recruitment might contribute to inflammation by directly 
increasing circulating concentrations of oxidized LDL that represent another stimulus for increased 
leukocyte adhesion. In addition, superoxide by depleting NO bioavailability fosters the acquisition 
of an inflammatory phenotype by endothelial cells. In fact, it has been shown that NO, by inducing 
the inhibitor B- an inhibitor of NFB, counteracts cytokine-induced upregulated expression of 
adhesion molecules by the endothelium [47, 48]. A relevant source of cytokines reinforcing the 
acquisition of inflammatory phenotype by endothelial cells is represented by T lymphocytes. The 
role of T lymphocytes in the development of atherosclerostic lesions in the macrovasculature is 
well documented [10]. Before plaque development, a contribution of lymphocytes in determining 
the inflammatory phenotype of endothelial cells in the microvasculature has been shown in mice 
lacking B and T cells. However T lymphocytes play a prominent role. The two main T lymphocyte 
subsets CD4+ and CD8+ both contribute significantly to leukocyte adhesion to post-capillary 
venules occurring in diet-induced hypercholesterolemia. In fact, depletion of each subset leads to 
marked reduction of microvascular leukocyte recruitment, and the administration of lymphocytes to 
immunodeficient mice restored venular inflammation. In addition, the reconstitution of lymphocyte 
deficient animals with splenocytes from IFN- deficient mice failed to restore leukocyte adhesion 
indicating a non redundant function of such cytokine in the establishment of the microvascular 
inflammatory phenotype upon hypercholesterolemia [25]. Similarly, mice lacking the p35 or the p40 
subunit of the heterodimeric cytokine IL-12 display reduced leukocyte adhesion to the 
microvasculature upon the establishment of diet-induced hypercholesterolemia [26]. As there is no 
obvious direct proinflammatory effect exerted by IL-12 on endothelial cells or leukocytes, it is likely 
that IL-12 effect on microvascular inflammation is indirect and possibly mediated by IFN-. Indeed 
IL-12 is pivotal in the polarization of T lymphocyte toward a type 1 phenotype characterized by IFN-
 expression and release upon activation [49]. T cell polarization occurs in secondary lymphoid 
tissues when antigens collected in periphery are presented to naïve T cells by professional antigen 
presenting cells (APC, e.g. dendritic cells) [50]. Sustained recognition of APC-borne MHC-bound 
antigen by T cell receptor along with appropriate costimulation are mandatory for naïve T cells 
activation. Interleukin-12 represents the key signal provided by APCs that induces epigenetic 
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modifications of gene expression in the T cell determining its commitment to the type 1 phenotype 
(IFN- but not IL-4 producing) [51]. Antigen presentation occurring in the absence of IL-12 favours 
the development of type 2 T cells producing IL-4 but not IFN-. It is worth noting that IL-12 shares 
the p40 subunit with IL-23, which in turn, plays a key role in the development of the IL-17-
producing proinflammatory CD4+ T cell subset Th17 implicated in chronic inflammation [52]. 
Therefore, the observations made in p40-deficient mice might be due to the deficiency of both Il-12 
and Il-23 and consequent blocked development of Th1 and Th17 subsets. Although the role of 
Th17 on microvascular inflammation associated to atherosclerosis has no been so far investigated, 
it has been shown that IL-17 synergized with IFN- to enhance IL-6, CXCL8, and CXCL10 
secretion [53]. 
Interleukin-18 has also been implicated in the induction of IFN- in atherogenesis. Gerdes and 
coworkers showed IL-18 production by infiltrating macrophages and important levels of IL-18 
receptor expression in human atheroma. IL-18 receptor was expressed by macrophages, ECs and 
smooth muscle cells [54]. Stimulation with IL-18 induced IL-6, IL-8, ICAM-1 and metalloproteinases 
expression. The study showed, for the first time, the ability of IL-18 alone or in combination with IL-
12 to induce IFN- production not only in macrophages but also by smooth muscle cells. 
Many studies indicated IFN- as a cytokine participating to atherosclerotic plaques development 
[10, 55]. Several mechanisms might link IFN- to vascular dysfunction: IFN- stimulates 
macrophages thereby enhancing their production of nitric oxide, pro-inflammatory cytokines and 
pro-trombotic and vasoactive factors. Additionally, IFN- stimulates superoxide production in 
endothelial cells as well as NADPH activity in monocytes and granulocytes [56-58]. In keeping, 
IFN--knockout mice display reduced oxidative stress in the microcirculation [26]. Notably, in 
conditions of reduced NO bioavailability, IFN- has been shown to promote LDL oxidation [59]. 
Furthermore, IFN- is a potent inducer of ICAM-1 expression on vascular endothelial cells [60] 
thereby increasing circulating leukocyte recruitment and might be implicated in the arteriolar 
dysfunction associated with hypercholesterolemia. 
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Microvascular inflammation and obesity 
 
Inflammatory phenotype of microvessels is associated with cardiovascular risk factors that favour 
atherosclerosis. In obese subjects the expanded adipose tissue is also characterized by activated 
phenotype of adipocytes and infiltrating cells such as macrophages and T cells. Expansion and 
activation of adipose tissue in obesity translates into increased release of adipose tissue derived 
mediators, including inflammatory cytokines such as TNF-, IL-1, IL-6 and adipokines [61]. In 
obese subjects as well as in animal models of obesity, increased local concentration of cytokines 
and adipokines in adipose tissue are able to induce evident signs of inflammation in the local 
microcirculation. In obese mice arterioles, capillaries and postcapillary venules of visceral adipose 
tissue undergo changes that are consistent with active inflammation [62]. Also, reduced blood flow 
in adipose tissue, due to arteriolar dysfunction with consequent induction of hypoxic state, has 
been observed. As a consequence, increased expression of HIF-1 alpha and capillary proliferation 
is also evident in obese adipose tissue [63]. In addition, leptin, resistin and other adipokines have 
been shown to inhibit endothelial dependent vasodilation [64]. Moreover, activation of capillary 
endothelium may contribute to the blood flow reduction due to increased leukocyte adhesion and 
platelet aggregation. In fact, in adipose tissue of obese animals, administration of neutralizing anti 
ICAM-1 antibodies improves capillary perfusion, likely by reducing vessel ploughing by leukocytes, 
but also reduces vascular permeability. This may indicate that leukocyte adhesion induces 
microvascular barrier dysfunction [62]. Similarly, adipose tissue venules display inflammatory 
phenotype with enhanced expression of P-selectin, E-selectin and ICAM-1 and increased 
leukocyte recruitment. Increased local levels of TNF- with parallel decreased adiponectin 
concentrations as well as increased oxidative stress likely contribute to enhanced adhesion 
molecules by endothelial cells as well as to the increased P-selectin expression on platelets 
accompanied by augmented platelet-leukocyte aggregates [62, 65]. Along with increased formation 
of leukocyte-platelet aggregates, in both obese subjects and animal models of obesity, reduced 
fibrinolysis and increased thrombogenicity are also evident. Increased levels of the leptin enhance 
the risk of thrombosis in obese human subjects. Activation of leptin receptor by its natural ligand 
induces the activation of phospholipase C and protein kinase C via intracellular calcium 
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mobilization by PI3K Akt signaling pathway. Impaired platelet aggregation is observed in both 
leptin and leptin receptor deficient mice. The pro-thrombotic activity of leptin is counteracted by 
adiponectin as suggested by the increased thrombi formation in adiponectin-knockout mice [66, 
67]. Adiponectin also inhibits inflammatory cells adhesion to the endothelium by counteracting 
TNF- induced NFB activation via cyclic AMP-dependent mechanism [68] and consequently 
inhibits endothelial adhesion molecules expression. [69]. In addition, adiponectin-dependent 
increased endothelial cell cytoskeleton stability reduces vascular permeability in response to TNF-
 or angiotensin II via a cyclic AMP dependent pathway. Conversely, leptin promotes capillary 
vascular fenestration and permeability [70]. 
Notably, during adipogenesis, leptin expression is increased while adiponectin production is 
markedly reduced. This suggests that leptin/adiponectin imbalance participates in promoting the 
vascular inflammatory phenotype observed in adipose tissue of obese animals, in particular the 
increased coronary microvascular permeability observed at early stages of obesity. Beside the 
local effects of increased adipokines levels occurring in hypertrophic adipose tissue, the 
accumulation of such factors in plasma elicit prime endothelial cells for activation in response to 
low concentration of inflammatory stimuli, causing the low-grade systemic inflammation that is 
associated to obesity [71, 72]. 
 
Microvascular inflammation and diabetes 
Hyperglycemia is an important trigger of oxidative stress. In insulin-independent tissues, local 
production of oxidants is enhanced along with the increase of cellular glucose uptake. 
Hyperglycemia stimulates superoxide production by glucose oxidase and NADPH oxidase. Such 
effect is mediated by protein kinase C activation [73-76]. 
Oxidative stress resulting from hyperglycemia has been implicated in the impaired vascular 
function that is associated with diabetes. Diabetes results in enhanced expression of the 
angiotensin 1 receptor as well as the p47 and gp91 subunits of the NADPH oxidase complex. In 
these conditions, AT1r antagonism or NADPH oxidase inhibition restores NO-dependent vascular 
function [77, 78]. 
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Hyperglycemia and oxidative stress are recognized as two major determinants of the increased 
leukocyte-endothelial cell interaction occurring in diabetes. Using intravital microscopy, Booth and 
colleagues showed that local glucose levels increased endothelial P-selectin expression along with 
leukocyte rolling, firm adhesion and migration in post capillary venules [79]. Moreover, similar 
effects are mimicked in vitro in endothelial cell cultured exposed to sera of diabetic patients or 
advanced glycation endproduct-albumin and are significantly reduced in vivo by protein C inhibition 
or the administration of insulin or SOD. In addition, a possible role for the receptor for advanced 
beta 2 integrin on 
leukocyte surface, has been proposed [65, 79-82]. 
Oxidative stress, hyperglycemia and increased leukocyte interaction with the endothelium have 
been linked to increased vascular permeability that is observed in animal models of diabetes and in 
diabetic subjects. Diabetes-associated retinopathy and nephropathy represent an example of 
major complications due to the loss of the endothelial barrier function . In fact, oxidative stress, 
hyperglycemia and increased leukocyte recruitment cause loss of perycytes and endothelial cells, 
basement membrane thickening as well as capillary closure in the retina. Consequent hypoxia 
stimulates angiogenesis. The blockade of the renin-angiotensin system by ACE inhibitors or by 
antagonists of the angiotensin receptor reduces retinal angiogenesis and the expression of VEGF 
and VEGFR [83-85]. PPARgamma, VGEF, protein kinase C and the renin-angiotensin system are 
believed to play a relevant role in diabetes-induced vascular permeability [86-90]. 
Increased platelet activation is associated with diabetes. This is thought to be, at least in part, 
dependent on a reduced capacity of NO to inhibit platelet activation possibly as a result of the 
oxidative stress associated with diabetes and consequent reduction of NO bioavailability [91-99]. 
 
Summary 
The evidence linking microvascular and inflammatory responses to cardiovascular risk factors 
indicates the existence of common events that initiate and promote these responses. Oxidative 
stress, reduced NO bioavailability, endothelial activation are common early features of 
microvascular responses to cardiovascular risk factors. Another important consequence of 
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exposure to such risk factors is the increased extent of tissue damage after ischemia reperfusion. 
For example, obese, hypercholesterolemic and diabetic animals display markedly increased 
microvascular oxidative stress and enhanced NADPH oxidase activation compared to animals 
without risk factors [100-104]. Furthermore, larger extent of leukocyte and platelets adhesion to 
endothelial cells in post-capillary venules is associated with hypercholesterolemia, obesity and 
diabetes. Increased leukocyte and platelet recruitment is associated to markedly enhanced 
vascular permeability after ischemia reperfusion. Finally, in the presence of risk factors the 
beneficial effects of ischemic preconditioning are severely attenuated [105]. 
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